Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UnitedHealth Group (UNH) reported Q3 2025 results showing strong top-line growth but significantly lower profitability. Total revenues were $113.2 billion, up 12% year over year, driven by Medicare Advantage growth and Optum Rx volume. Diluted EPS was $2.59 versus $6.51 a year ago as medical costs rose faster than premiums.
Profitability compressed: the medical care ratio increased to 89.9% from 85.2%, reflecting Medicare funding reductions, higher care utilization, and seasonal impacts from the Inflation Reduction Act on Part D. Operating margin fell to 3.8% from 8.6% and earnings from operations declined 50% to $4.3 billion.
Segment trends: UnitedHealthcare revenue grew 16% with 795,000 more people served, primarily in Medicare Advantage. Optum revenues rose 8% (Optum Rx up 16%), while Optum Health profitability was pressured by Medicare dynamics and elevated cost trends. For the nine months, cash flows from operations were $18.6 billion, supporting ongoing dividends and repurchases disclosed in the period.
UnitedHealth Group (UNH) furnished an 8-K announcing its third quarter 2025 results. The company disclosed that it issued a press release detailing Q3 2025 performance, which is provided as Exhibit 99.1 and incorporated by reference.
The disclosure under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act. The filing also includes the Cover Page Interactive Data File labeled as Exhibit 104.
Frederick W. McNabb III, a director of UnitedHealth Group Inc. (UNH), reported receipt of 289 deferred stock units as compensation on 10/01/2025. The units were issued at $0 and are immediately vested but must be retained until he leaves the Board. Following the grant, Mr. McNabb beneficially owns 14,341 shares (direct). The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Timothy P. Flynn, a director of UnitedHealth Group Inc. (UNH), received 272 deferred stock units on 10/01/2025 as regular quarterly director compensation at a reported price of $0. The filing shows 9,810 shares beneficially owned following the transaction and an additional 6,033 shares held indirectly by trust. The form explains these deferred stock units are immediately vested but must be retained until the director leaves the board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.
UnitedHealth Group (UNH) director Kristen L. Gil received 162 shares of common stock as regular quarterly director compensation on 10/01/2025 at no cash price reported. After the grant, Ms. Gil directly beneficially owns 1,900 shares and indirectly owns 3,800 shares through a trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing identifies the reporting person as a director and notes the shares were granted as routine director compensation.
UnitedHealth Group (UNH) director Valerie C. Montgomery Rice, M.D. was granted 270 deferred stock units on 10/01/2025 as part of regular quarterly director compensation. The units are immediately vested but must be held until she leaves the board. After the grant, her reported beneficial ownership of common stock is 6,897 shares, held directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
This Form 4 reports that Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), was granted 260 deferred stock units as director compensation on 10/01/2025. The units were granted at a $0 per-unit price and are described as immediately vested but required to be retained until the director leaves the Board. After the reported grant, the filing shows 1,516 shares (or equivalent units) beneficially owned by Mr. Baker. The form was signed by Faraz A. Choudhry, Attorney-in-Fact on 10/03/2025.
Michele J. Hooper, a director of UnitedHealth Group (UNH), was granted 162 deferred stock units on 10/01/2025 as regular quarterly director compensation. The grant was recorded at a reported price of $0 and increases her reported beneficial ownership to 40,877 shares following the transaction. The filing states the deferred stock units are immediately vested but must be retained until the director ends service on the Board. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025.
John H. Noseworthy, a director of UnitedHealth Group Inc. (UNH), reported acquisition of 261 deferred stock units on 10/01/2025 as part of regular quarterly director compensation. The units were granted at $0 (deferred awards) and are immediately vested but must be held until the director leaves the Board. After the transaction, Dr. Noseworthy beneficially owns 6,693 shares (direct). The Form 4 was signed by attorney-in-fact Faraz A. Choudhry on 10/03/2025. The filing indicates this is a single reporting person filing and identifies the reporter as a Director of the issuer.
Timothy J. Noel, Chief Executive Officer, UHC, reported a non-derivative acquisition of common stock for UNITEDHEALTH GROUP INC (UNH) dated 09/23/2025. The transaction is coded A and is described as dividend equivalents paid on outstanding restricted stock units, which follow the same vesting terms as the underlying RSUs and are forfeited if the RSUs do not vest. The filing records a $0 price for the acquisition and shows 9,286.339 shares beneficially owned following the reported transaction(s). The form was signed by an attorney-in-fact on behalf of Mr. Noel on 09/25/2025.
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
